Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

By R. V. van Vollenhoven, R. Fleischmann, S. Cohen, E. Lee, J. A. García Meijide, Sylke Wagner, Š. Forejtová, S. Zwillich, D. Gruben, T. Koncz and 4 more. New England Journal of Medicine, 2012

904 citations recorded by the source corpus.

Subfields: Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/905ec0aa9e3dd1b86c8ad80596f7615605c8eac8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Rheumatology

1. J. O’Shea

Citations in the corpus

• JAK inhibition as a therapeutic strategy for immune and inflammatory diseases (2017, background): “1(14,18)] hexacosa‐1(24),2,4,9,14(26),15,17,20,22‐nonaene (SB1578), a potent inhibitor of Janus kinase 2/FMS‐like tyrosine kinase‐3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.”